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OBJECTIVES Our study goal was to analyze whether gene variants of angiotensin II type 2-receptor
(AT2-R) modulate the effects of angiotensin II on the left ventricle (LV).
BACKGROUND Experimental data suggest that angiotensin II modifies ventricular growth responses via
angiotensin II type 1-receptors (AT1-R) and AT2-R.
METHODS In 120 white, young male subjects with normal or mildly elevated blood pressure, we assessed
plasma angiotensin II and aldosterone concentrations (RIA), 24-h urinary sodium excretion,
24-h ambulatory blood pressure and LV structure (two-dimensional guided M-mode
echocardiography). The intronic 11675 G/A polymorphism of the X-chromosomal located
AT2-R gene was investigated by single-strand conformational polymorphism analysis and
DNA-sequencing.
RESULTS Hypertensive subjects with the A-allele had a greater LV posterior (11.0 6 1.3 vs. 9.9 6
1.3 mm, p , 0.001), septal (11.8 6 1.4 vs. 10.1 6 1.2 mm, p , 0.001) and relative wall
thickness (0.44 6 0.06 vs. 0.39 6 0.06, p , 0.01) as well as LV mass index (138 6 23 vs.
120 6 13 g/m2, p , 0.001) than those with the G-allele. Confounding factors (i.e., body
mass index and surface area, plasma angiotensin II, sodium excretion, systolic and diastolic
ambulatory blood pressure) were similar between the two genotypes. In normotensive
subjects, relative wall thickness (0.36 6 0.05 vs. 0.35 6 0.05) and LV mass index (115 6 21
vs. 112 6 17 g/m2) were nearly identical across the two genotypes, with similar confounding
variables.
CONCLUSIONS Our data indicate that the X-chromosomal located 11675 G/A-polymorphism of the AT2-R
gene is associated with LV structure in young male humans with early structural changes of
the heart due to arterial hypertension. (J Am Coll Cardiol 2001;37:175–82) © 2001 by the
American College of Cardiology
Left ventricular (LV) structure and function are important
predictors of cardiovascular morbidity and mortality in
cardiac patients and in the general population (1,2).
Echocardiographic LV hypertrophy increases the risk of
cardiovascular morbid events in primary and secondary
hypertension (3–5) but also indicates a higher risk for the
development of arterial hypertension in normotensive sub-
jects (6,7). Constitutional and environmental factors have
been identified that influence cardiac structural adaptation
to an increased preload and afterload imposed on the LV
(8–11). Studies of monozygotic and dizygotic twins have
suggested that inherited factors are also of pathogenic
relevance (12,13).
The activity of the renin angiotensin system (RAS)
profoundly influences blood pressure (BP) and cardiovascu-
lar disease (14–17). Experimental studies have documented
the growth stimulating and regulating effects of angiotensin
II on myocardial cells (14,15). In hypertensive subjects
impaired suppression of the RAS or, conversely, increased
sensitivity to angiotensin II appeared to act as a stimulus for
LV hypertrophy (18,19).
Over the last 5 years various genes of the RAS have been
associated with cardiovascular disease (20–25). However,
these studies yielded conflicting results: some found a
positive association of the risk for myocardial infarction with
the angiotensin-converting enzyme D-allele, whereas others
did not (20,21). Similarly, the T235-variant of the angio-
tensinogen gene was found to be associated with essential
hypertension, but subsequent studies in monozygotic and
dizygotic twin pairs did not confirm the earlier observation
(22,23). More recent studies have focused on variants of
genes downstream of the angiotensinogen and angiotensin-
converting enzyme in the RAS cascade.
The angiotensin II type 1-receptor (AT1-R) appears to
be the primary receptor that mediates the vasoconstrictor
and growth promoting effects of angiotensin II in humans
(15). The gene that encodes AT1-R has been intensively
investigated as a risk factor for hypertension and cardiovas-
cular disease (23,26). The nucleotide substitution (A/C in
position 11166) in the gene of the AT1-R is located in the
39 untranslated part of the gene, and increased frequency of
the C-allele has been reported in patients with arterial
hypertension, increased aortic stiffness, LV hypertrophy and
coronary vasoconstriction (24,25). However, other reports
did not confirm such an association between the 11166
A/C polymorphism and cardiovascular disorders (23).
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Up to now, most of the studies have been carried out with
respect to AT1-R genotypes and related effects. In contrast,
function, regulation and signal transduction of the angio-
tensin II type 2-receptor (AT2-R) are only partly known
(27). Angiotensin II type 2-receptor expression is restricted
to a few tissues in adults. It is upregulated in the endothe-
lium under pathological circumstances, such as new intima
formation after vascular injury and in the heart after
myocardial infarction or during cardiac remodeling (28–30).
The expression patterns and regulation of the angiotensin II
receptors differ among species with the AT2-R being the
predominant receptor subtype in the human heart (30–32).
The AT2-R gene is located on the X-chromosome and
spans about 5 kb (33). The gene structure and the complete
nucleotide sequence of the human AT2-R gene, which
includes the promoter region, was elucidated in 1995 (33).
Regulatory elements are located in the first intron in
addition to the promoter region (34). The AT2-R decreases
BP, exerts antiproliferative effects on endothelial and vas-
cular smooth muscle cells (15,35–38) and modifies LV
fibrogenic (39) and growth responses (40). The signaling via
AT2 is essential for the development of pressure overload-
mediated cardiac hypertrophy in transgenic mice (41),
whereas in isolated adult rat hearts AT2 inhibition amplifies
the LV growth response to angiotensin II (40).
The pathogenic effects of the AT2-R for cardiac struc-
tural processes in humans are far from being understood. To
the best of our knowledge no data have been reported in
humans so far. We thought that the functional character-
ization of the human AT2-R genotypes is an attractive
approach to elucidate the pathogenic role of AT2-R in
cardiovascular diseases, particularly since no AT2-R agonist
or antagonist is available for human use, and, thus, no
pharmacological experiments have been carried out to elu-
cidate the physiological and pathophysiological role of
AT2-R. Therefore, we tested whether the 11675G/A
polymorphism is associated with cardiac structural adapta-
tion to an increased afterload in a homogeneous study
cohort of young male white subjects.
METHODS
Study population. By advertising we elicited the partici-
pation of young white male students at the campus of the
University Erlangen-Nu¨rnberg. One-hundred twenty sub-
jects were consecutively enrolled in the study up to a number
of 60 subjects in the normotensive range and 60 subjects
with mildly elevated BP. According to the World Health
Organization/International Society of Hypertension
(WHO/ISH) criteria, an average BP of $140 mm Hg
systolic or $90 mm Hg diastolic was said to be hypertensive
(42). The study protocol was approved by the clinical
investigation and ethics committees of the University
Erlangen-Nu¨rnberg, Germany, and informed consent was
given before study inclusion.
Study inclusion criteria were: age between 20 and 40
years, male gender, white, no current or previous treatment
for arterial hypertension, no cardiovascular disease (with the
exception of mildly elevated BP) and no secondary hyper-
tension or WHO stage III hypertensive disease. Therefore,
exclusion criteria were: advanced hypertensive fundoscopic
changes, myocardial infarction or any other evidence of
coronary artery disease, congestive heart failure or previous
cerebrovascular event and hepatic or renal insufficiency.
Each participant underwent a thorough clinical work-up
described elsewhere in detail (19).
BP measurements. To obtain correct BP readings a stan-
dard sphygmomanometer was used, and the cuff size was
adjusted according to the participant’s arm circumference.
Four casual BP readings were taken in our outpatient clinic
on at least two different occasions (at least four weeks apart)
after 5 min of rest in a standardized fashion. Subjects who
had been allocated to one of the two groups according to the
screening BP, but later failed to fulfill all study entry criteria,
were replaced.
Ambulatory 24-h BP measurements were taken with an
automatic portable device (Spacelab No. 90207, Redmont,
California). Measurement intervals were every 15 min
during the day (defined from 7:00 to 22:00 h) and every
30 min during the night (43). In parallel, a 24-h urinary
sodium excretion, which represents a rough but valuable
estimate of daily sodium intake, was measured (18,19).
Parameters of the RAS. Blood samples for the determi-
nation of plasma angiotensin II and serum aldosterone levels
were collected from patients who were in the supine
position after 1 h of complete rest. For plasma angiotensin
II measurements, blood was collected into prechilled 10 ml
syringes, prepared with EDTA 125 mmol and phenantro-
line 26 mmol (Merck, Darmstadt, Germany) to inhibit the
angiotensin-converting enzyme. The samples were centri-
fuged for 10 min at 4°C immediately after collection and
rapidly stored after centrifugation at 221°C, but analyzed
within three months. Plasma samples were extracted, and,
after purification of the samples, immunoreactive angioten-
sin II was measured in duplicate by radioimmunoassay with
antiserum, as previously described (19). The coefficient of
variation was ,5%. Serum aldosterone was measured by a
commercially available radioimmunoassay kit (Aldosterone
Maia, Serono, Freiburg, Germany).
Echocardiography. Two-dimensional guided M-mode
echocardiography was performed using an ultrasonoscope
(Picker-Hitachi CS 192; Tokyo, Japan) with a 2.5 MHz
probe (for details see [18,19]). All echocardiographic read-
Abbreviations and Acronyms
AT1-R 5 angiotensin II type 1-receptor
AT2-R 5 angiotensin II type 2-receptor
BP 5 blood pressure
LV 5 left ventricle
PCR 5 polymerase chain reaction
RAS 5 renin angiotensin system
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ings were evaluated by two investigators independently. The
echocardiographic reading was done blindly with respect to
other clinical data and, in particular, to the genotyping of
our subjects (as indicated by different locations of the
echocardiographic and genetic evaluation). Relative wall
thickness taken as a parameter for concentric LV hypertro-
phy was calculated as two times posterior wall thickness
divided by end-diastolic diameter. Left ventricular mass was
calculated according to the American Society of Echocar-
diography recommendations (44) but was then corrected
according to the suggestions of Devereux and coworkers
(45). Coefficients of variation for all structural parameters
were less than 10%.
Mutation screening and genotyping. Genomic DNA was
extracted from 2 to 5 ml of whole blood by standard
methods using a commercially available kit (QIAamp Blood
Midi Kit, QIAGEN GmbH, Hilden, Germany). In a
previous study the complete coding region of the human
AT2-R gene (1,092 base pair [bp]) as well as intron 1
(152 bp) were screened in 92 patients with cardiovascular
diseases. Eight overlapping PCR-fragments of 142 to
297 bp were used. SSCP was run at 4°C and room
temperature on 10% polyacrylamide gels (49:1; acrylamide:
bisacrylamide). Two variants significantly altered the migra-
tion pattern of the corresponding PCR-products. Sequenc-
ing of aberrant products revealed one frequently occurring
intronic polymorphism (11675 G/A) (Fig. 1) and one rare
amino acid substitution (Gly-21-Val).
Since the 11675 G/A polymorphism does not alter any
known enzyme restriction site, the genotyping in larger
samples was based on repeated SSCP analysis. In brief, after
amplification using primers AT2.intron 1F (59-ATT ACG
TCC CAG CGT CTG AG-39) and AT2.intron1R (59-
ATA AAT CAG CTT GCT TAG TGC C-39), a PCR-
fragment of 255 bp was produced. SSCP-gels were run for
16 to 18 h at 7 V/cm at 4°C. Bands were visualized by silver
staining (46).
Three different DNA samples that represented the three
genotypes (G-, A-, GA) were analyzed as controls on every
gel (Fig. 1). All ambiguous samples were analyzed a second
time, as proposed by others (47,48), and a second analysis
was also performed for every 10th sample for control
reasons.
Statistical analysis. A power calculation was used to cal-
culate the sample size with a 95% confidence (type I error:
a 5 0.05) and 90% power (type II error: b 5 0.10)
assuming that a difference of d 5 12 g/m2 for LV mass
index (with a standard deviation of s 5 20 g/m2) is of
clinical relevance (49).
All statistical analyses were carried out using SPSS
software (SPSS for Windows, SPSS Inc., Chicago, Illinois).
In particular, two-way analysis of variance was used to
detect any significant difference between carriers of the
A-allele vs. G-allele of the X-chromosomal located 11675
G/A polymorphism of the AT2-R gene in the normotensive
versus the hypertensive group.
Finally, stepwise multiple linear regression analysis was
used to examine the determinants of LV mass and septal
and posterior wall thickness in the whole study cohort: the
a-level for entry and removal of terms at each forward step
was 0.10. All data in the text are given as x 6 1 standard
deviation and in the figures as x 6 95% confidence interval.
Two-tailed values of p , 0.05 were considered statistically
significant.
RESULTS
The clinical characteristics of our study population are given
in Table 1. In our homogenous study cohort of young male
white subjects, the frequency of the A-allele was 57% and of
the G-allele 43%. When classified according to the WHO,
the G-allele frequency was 46% in the hypertensive and 41%
in the normotensive subjects, which was not significantly
different (x2 test: p . 0.20).
In the whole study group LV structural parameters were
linked to the 11675 G/A polymorphism of the AT2-R
gene (Table 2). Subjects with the A-allele of the AT2-R
gene had a greater posterior (p , 0.025) and septal wall
thickness (p , 0.001) than those with a G-allele of AT2-R
gene. Relative wall thickness and LV mass were greater in
subjects with the A-allele than they were in those with the
Figure 1. (a) Part of the nucleotide sequence of the human angiotensin II
type 2-receptor gene. The position of the G.A substitution at position
11675 is marked with an arrow. First row: DNA-sequence of a patient
carrying the G-allele. Second row: DNA-sequence of a patient carrying
both alleles (G/A). Third row: DNA-sequence of a patient carrying the
A-allele. (b) Representative example of a SSCP-gel showing the charac-
teristic band-pattern of the 11675 G/A polymorphism after denaturing
and loading on a 10% PAA gel at 4°C. Lane 1: PCR-product of a
heterozygote patient designated G/A. Lane 2: PCR-product of a patient
carrying the G-allele (G). Lane 3: PCR-product of a patient carrying the
A-allele (A). Lane 4 and 5: PCR-products of patients carrying the
G-allele.
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G-allele of the AT2-R gene (p , 0.02). This difference in
LV mass was not related to body surface area or body mass
index, 24-h ambulatory systolic or diastolic BP, urinary
sodium excretion, plasma angiotensin II or serum aldoste-
rone concentrations since these potentially confounding
cofactors were similar in the two genotypes of the AT2-R
(Table 2). Accordingly, analysis of covariance revealed that
the association of the 11675 G/A polymorphism of the
AT2-R gene with LV mass (p 5 0.003) and relative wall
thickness (p 5 0.014) were independent of body mass index,
24-h ambulatory systolic and diastolic BP, urinary sodium
excretion, plasma angiotensin II and serum aldosterone
concentrations.
Hypertensive subjects (according to WHO criteria) with
the A-allele of the AT2-R gene had a greater posterior wall
thickness (p , 0.001), septal wall thickness (p , 0.001),
relative wall thickness (p , 0.001) and LV mass index (p ,
0.01) than hypertensive subjects with the G-allele of the
AT2-R (Tables 3 and 4, Fig. 2 and 3). Ambulatory and
casual BP, body mass index, urinary sodium excretion,
plasma angiotensin II and serum aldosterone concentrations
were similar between the two genotypes of the AT2-R gene
(Table 3). Analysis of covariance confirmed that the 11675
G/A polymorphism of the AT2-R gene was associated with
LV mass (p , 0.001), relative wall thickness (p , 0.05),
posterior (p , 0.01) and septal wall thickness (p , 0.001),
independent of confounding factors. In contrast, no signif-
icant difference of LV structural parameters between the A-
and G-allele carriers was found in the normotensive sub-
groups (Table 4).
Similarly, when our subjects were post hoc divided
according to 24-h ambulatory BP criteria ($130 mm Hg or
$80 mm Hg [50]), the 11675 G/A polymorphism of the
AT2-R modulated LV structure in the hypertensive (n 5
46) but not in the normotensive individuals (n 5 74).
Hypertensive subjects with the A-allele of AT2-R revealed
an increased LV mass index (132 6 25 vs. 116 6 14 g/m2,
p 5 0.011) and relative wall thickness (0.43 6 0.06 vs.
0.37 6 0.06, p 5 0.004) with similar confounding factors
such as 24-h ambulatory systolic and diastolic BP, body
mass index, urinary sodium excretion, plasma angiotensin II
Table 1. Characteristics of the Whole Study Cohort (n 5 120), the Normotensive (n 5 60) and











Age (yrs) 26 6 3 26 6 2 26 6 3
Height (m) 1.81 6 0.07 1.81 6 0.07 1.82 6 0.07
Weight (kg) 78.7 6 10.4 75.2 6 8.5 82.9 6 11
Body surface area (m2) 1.99 6 0.15 1.95 6 0.13 2.04 6 0.15
Body mass index (kg/m2) 23.9 6 2.8 23.0 6 2.2 24.9 6 3.1
Casual systolic BP (mm Hg) 137 6 17 123 6 7 153 6 9
Casual diastolic BP (mm Hg) 87 6 11 79 6 5 97 6 8
Ambulatory systolic BP (mm Hg) 127 6 10 122 6 7 134 6 10
Ambulatory diastolic BP (mm Hg) 76 6 7 72 6 5 79 6 8
Plasma angiotensin II (pg/ml) 8.3 6 3.9 7.9 6 3.9 8.73 6 3.9
Plasma aldosterone (pg/ml) 125 6 39 121 6 33 130 6 45
Sodium excretion (mmol/day) 190 6 70 191 6 62 190 6 80
Echocardiographic data
Posterior wall thickness (mm) 9.8 6 1.4 9.1 6 1.0 10.5 6 1.3
Septal wall thickness (mm) 10.3 6 1.5 9.7 6 1.2 11.0 6 1.5
End-diastolic diameter (mm) 51.3 6 3.5 51.3 6 3.4 51.3 6 3.6
End-systolic diameter (mm) 32.6 6 3.6 32.9 6 3.5 32.3 6 3.7
Left ventricular mass (g) 241 6 48 221 6 38 265 6 47
Left ventricular mass index (g/m2) 121 6 22 114 6 19 130 6 21
Relative wall thickness (2) 0.38 6 0.06 0.36 6 0.05 0.41 6 0.07
BP 5 blood pressure; mean 6 1 SD.
Table 2. Clinical and Echocardiographic Data Stratified
According to the X-Chromosomal Located11675 G/A







Body weight (kg) 77.6 6 9.86 79.6 6 10.7 . 0.20
Body surface area (m2) 1.97 6 0.13 2.00 6 0.15 . 0.20
Body mass index (kg/m2) 23.7 6 2.9 24.0 6 2.8 . 0.20
Casual systolic BP (mm Hg) 138 6 18 136 6 16 .0.20
Casual diastolic BP (mm Hg) 88 6 11 87 6 11 . 0.20
Ambulatory systolic BP
(mm Hg)
129 6 10 126 6 10 0.13
Ambulatory diastolic BP
(mm Hg)
76 6 7 75 6 8 . 0.20
Plasma angiotensin II (pg/ml) 8.4 6 3.6 8.2 6 4.2 . 0.20
Serum aldosterone (pg/ml) 119 6 34 130 6 42 . 0.20
Sodium excretion (mval/day) 192 6 74 188 6 67 . 0.20
Posterior wall thickness (mm) 9.4 6 1.2 10.0 6 1.5 0.025
Septal wall thickness (mm) 9.8 6 1.3 10.8 6 1.6 0.001
Diastolic diameter (mm) 51.6 6 3.3 51.0 6 3.7 . 0.20
Relative wall thickness (2) 0.37 6 0.06 0.39 6 0.07 0.021
Left ventricular mass (g) 229 6 37 250 6 53 0.016
BP 5 blood pressure; mean 6 1 SD.
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and serum aldosterone concentrations (data not shown).
Again, analysis of covariance indicated an independent
association of the AT2-R gene with LV mass (p , 0.02),
relative wall thickness (p , 0.05) and posterior (p , 0.02)
and septal wall thickness (p , 0.001).
In the stepwise multiple regression analysis for posterior
wall thickness, the 11675 G/A polymorphism of the
AT2-R gene (p 5 0.01), urinary sodium excretion (p 5
0.002), body mass index (p , 0.001) and 24-h ambulatory
systolic BP (p , 0.001) emerged as independent parame-
ters. Similarly, determinants for septal wall thickness were
the 11675 G/A polymorphism of the AT2-R (p , 0.001),
urinary sodium excretion (p 5 0.03), body mass index (p 5
0.001) and 24-h ambulatory systolic BP (p , 0.001). Left
ventricular mass was independently associated with the
11675 G/A polymorphism of the AT2-R gene (p 5 0.006),
body mass index (p , 0.001) and 24-h ambulatory systolic
BP (p 5 0.02).
DISCUSSION
AT2-R gene and LV structure. The principal finding of
our study is that the 11675 G/A polymorphism of the
X-chromosomal AT2-R gene is associated with LV struc-
tural changes in young male subjects with mildly elevated
BP. The A-allele carriers had a greater LV mass and relative
wall thickness than G-allele carriers, independent of other
determinants of LV structure. The association of LV mass
with the AT2-R gene polymorphism was most striking in
hypertensive subjects, regardless of the definition used for
arterial hypertension (Fig. 2 and 3). Elevated BP leads
primarily to a thickening of the LV wall due to an increased
afterload and, as a consequence, to a concentric remodeling
of the LV indicated by an increased relative wall thickness
and LV mass.
The association of the 11675 G/A polymorphism of the
AT2-R gene with LV mass was not affected by other
confounding variables that are well known to modulate early
structural processes of the LV to an increased pressure load
(51). Similarly, body constitution known to modify the
degree and pattern of LV hypertrophy in humans (11,52)
did not bias our results.
Biological relevance of AT2-R gene. Of the two
7-transmembrane angiotensin II receptor subtypes identi-
fied in humans up to now, most of the known effects of the
renin angiotensin system are mediated by the AT1-R (53).
In contrast, regulation and signal transduction of the
AT2-R are still far from being understood. In the adult
AT2-R expression is restricted to a few tissues. It is
upregulated under circumstances such as cardiac remodeling
and infarction (28–30). The single copy human AT2-R
gene is located on the X-chromosome, spans about 5 kb and
comprises two short noncoding exons (68 bp and 95 bp), 2
introns of 152 bp and 1,207 bp and exon 3 (.2,300 bp),
which contains the entire protein coding region (33).
Sequence elements located on the introns are necessary for
efficient human AT2-R transcription (34). The newly de-
Table 3. Clinical Data Stratified According to the 11675 G/A Polymorphism of the Angiotensin II AT2-Receptor Gene













Body surface area (m2) 1.93 6 0.11 1.96 6 0.14 2.02 6 0.15 2.06 6 0.15 . 0.20 , 0.001
Body mass index (kg/m2) 23.1 6 2.3 22.9 6 2.2 24.4 6 3.3 25.5 6 2.8 . 0.20 , 0.001
Casual systolic BP (mm Hg) 123 6 7 123 6 7 154 6 10 152 6 9 . 0.20 , 0.001
Casual diastolic BP (mm Hg) 79 6 5 79 6 6 97 6 9 98 6 6 . 0.20 , 0.001
Ambulatory systolic BP (mm Hg) 124 6 7 121 6 6 134 6 11 133 6 9 . 0.20 , 0.001
Ambulatory diastolic BP (mm Hg) 73 6 5 72 6 5 79 6 7 80 6 8 . 0.20 , 0.001
Plasma angiotensin II (pg/ml) 8.7 6 3.8 7.3 6 4.0 8.1 6 3.5 9.3 6 4.3 . 0.20 . 0.20
Serum aldosterone (pg/ml) 116 6 30 124 6 35 121 6 37 138 6 51 . 0.20 . 0.20
Sodium excretion (mval/day) 189 6 59 190 6 64 194 6 90 186 6 72 . 0.20 . 0.20
BP 5 blood pressure; mean 6 1 SD.
Table 4. Echocardiographic Data Stratified According to the 11675 G/A Polymorphism of the Angiotensin II AT2-Receptor Gene













Posterior wall thickness (mm) 8.95 6 1.1 9.19 6 1.0 9.94 6 1.3 11.0 6 1.3 0.007 , 0.001 0.036
Septal wall thickness (mm) 9.49 6 1.2 9.89 6 1.2 10.1 6 1.2 11.8 6 1.4 , 0.001 , 0.001 0.007
Diastolic diameter (mm) 51.4 6 3.4 51.2 6 3.5 51.8 6 3.2 50.9 6 3.9 . 0.20 . 0.20 NS
Relative wall thickness (2) 0.35 6 0.05 0.36 6 0.05 0.39 6 0.06 0.44 6 0.06 0.009 , 0.001 0.049
Left ventricular mass (g) 216 6 35 225 6 40 243 6 34 283 6 49 0.006 , 0.001 0.036
Left ventricular mass index (g/m2) 112 6 17 115 6 21 120 6 13 138 6 23 0.014 , 0.001 0.041
Mean 6 1 SD. Please note that a significant interaction between normotension/hypertension and G/A allele carriers for structural parameters of left ventricular structure was
found (p , 0.05).
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tected intronic variant is located 29 bp before the start of
exon 2, close to the region that is important for transcrip-
tional activity of the human AT2-R gene (34).
Stimulation of the AT2-R has been shown to exert
antiproliferative effects in rat coronary endothelial cells,
vascular smooth muscle cells and adrenocortical cells (35–
37). The signaling via AT2 is essential for the development
of pressure overload-mediated cardiac hypertrophy in trans-
genic mice (41), whereas in adult hypertrophied rat hearts
AT2-R blockade amplifies the immediate LV growth re-
sponse to angiotensin II (40). In this study we observed that
the AT2-R gene is associated with LV structural adaptive
processes in hypertensive subjects prone to develop myocar-
dial hypertrophy to an increased afterload. At the moment
it is not yet understood whether the variant of the AT2-R
gene directly affects the AT2-R function or gene expression
or is in linkage disequilibrium with yet unknown polymor-
phisms in neighboring genes. However, since the 1675 G/A
polymorphism is located in a gene region that is involved in
transcriptional control of the AT2-R gene expression, it is
tempting to speculate that it may affect gene expression and
subsequently LV morphology. Interestingly, the antihyper-
trophic actions of AT2-R in experimental animals were
more pronounced in hypertrophied hearts.
Study limitations. Our results are restricted to young male
white subjects. Therefore, we cannot extrapolate that the
11675 G/A polymorphism is associated with LV structure
in older subjects or in subjects with more severe arterial
hypertension, that is, excessive increase in afterload imposed
on the LV. Conversely, since we examined a homogenous
study population, our study clearly has some advantages.
None of the subjects included had ever received or was on
any current antihypertensive or cardiovascular medication,
thereby ruling out any potential effect of previous antihy-
pertensive therapy (55,56). Moreover, the results are ex-
tremely unlikely to be due to an unexpected mixture of
population in our study center because the local German
population is ethnically homogenous, and subjects of other
nationality have been excluded. Finally, we did not fully
account for the exercise-induced physiological hypertrophy
as a potential underlying confounding element. However,
there is no rationale why the 11675 A genotype of the
AT2-R gene should exercise more than the G-allele carriers.
Conclusions. The current data indicate that the 11675
G/A polymorphism of the AT2-R gene is associated with
LV structure in young male subjects, in particular in those
with mildly elevated BP. The influence of the G/A geno-
type of the AT2-R on the LV is independent of body size,
plasma angiotensin II, serum aldosterone and the hemody-
namic load as assessed by 24-h ambulatory BP monitoring.
Figure 2. Left ventricular mass in normotensive and hypertensive subjects
classified according to the X-chromosomal located 11675 G/A polymor-
phism of the angiotensin II AT2-receptor gene. Solid circle5 A-allele;
solid square5 G-allele. Data are given by means (symbols) 6 95%
confidence interval.
Figure 3. Posterior, septal and relative wall thickness in normotensive and hypertensive subjects classified according to the X-chromosomal located 11675
G/A polymorphism of the AT2-receptor gene. Solid circle5 A-allele; solid square 5 G-allele. Data are given by means (symbols) 6 95% confidence
interval.
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Thus, our data suggest first that the AT2-R subtype may be
functional in humans and secondly that it may modulate LV
morphology in mild essential hypertension.
Reprint requests and correspondence: Dr. Roland E.
Schmieder, Department of Medicine IV, University Erlangen-
Nu¨rnberg, Breslauer Str. 201, 90471 Nu¨rnberg, Germany. E-mail:
Roland.Schmieder@rzmail.uni-erlangen.de.
REFERENCES
1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prog-
nostic implications of echocardiographically determined left ventricu-
lar mass in the Framingham Heart study. N Engl J Med 1990;
322:1561–6.
2. Messerli FH. Antihypertensive therapy—going to the heart of the
matter. Circulation 1990;81:1128–35.
3. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH.
Relation of left ventricular mass and geometry to morbidity and
mortality in uncomplicated essential hypertension. Ann Intern Med
1991;114:345–52.
4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre´ PE.
The prognostic importance of left ventricular geometry in uremic
cardiomyopathy. J Am Soc Nephrol 1995;5:2024–31.
5. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The
prognostic role of left ventricular hypertrophy in patients with or
without coronary artery disease. Ann Intern Med 1992;117:831–6.
6. De Simone G, Devereux RB, Roman MJ, Schlussel Y, Alderman MH,
Laragh JH. Echocardiographic left ventricular mass and electrolyte
intake predict arterial hypertension. Ann Intern Med 1991;114:202–9.
7. Post WS, Larson MG, Levy D. Impact of left ventricular structure on
the incidence of hypertension. Circulation 1994;90:179–85.
8. Messerli FH, Sundgaard-Riise K, Ventura HO, Dunn FG, Oigmann
W, Frohlich ED. Clinical and hemodynamic determinants of left
ventricular dimensions. Arch Intern Med 1984;144:477–81.
9. Liebson PR, Grandits G, Prineas R, et al. Echocardiographic corre-
lates of left ventricular structure among 844 mildly hypertensive men
and women in the Treatment of Mild Hypertension Study
(TOMHS). Circulation 1993;87:476–86.
10. Verdecchia P, Schillaci G, Boldrini F, Guerrieri M, Porcellati C. Sex,
cardiac hypertrophy and diurnal blood pressure variations in essential
hypertension. J Hypertens 1992;10:683–92.
11. Messerli FH, Sundgaard-Riise K, Reisen ED. Dimorphic cardiac
adaptation to obesity and arterial hypertension. Ann Intern Med
1983;99:757–61.
12. Adams TD, Yanowitz FG, Fisher AG, et al. Heritability of cardiac
size: an echocardiographic and electrocardiographic study of monozy-
gotic and dizygotic twins. Circulation 1985;71:39–44.
13. Bielen E, Fagard R, Amery A. Inheritance of heart structure and
physical exercise capacity: a study of left ventricular structure and
exercise capacity in 7-year-old twins. Eur Heart J 1990;11:7–16.
14. Geenen DL, Malhotra A, Scheuer J. Angiotensin II increases cardiac
protein synthesis in adult rat heart. Am J Physiol 1993;265:H238–43.
15. Timmermans PB, Wong PC, Chiu AT, Herblin WF, et al. Angio-
tensin II receptors and angiotensin II receptor antagonists. Pharmacol
Rev 1993;45:205–51.
16. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure.
Kidney Int 1987;31:1402–15.
17. Levine TB, Francis GS, Goldsmith RS, Simon AB, Cohn JN. Activity
of the sympathetic nervous system and renin angiotensin system
assessed by plasma hormone levels and their relation to hemodynamic
abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659–
66.
18. Schlaich MP, Schobel HP, Langenfeld MRW, Hilgers K, Schmieder
RE. Inadequate suppression of angiotensin II modulates left ventric-
ular structure in humans. Clin Nephrol 1998;49:153–9.
19. Schmieder RE, Langenfeld MRW, Friedrich A, Schobel HP, Gatzka
CD, Weihprecht H. Angiotensin II related to sodium excretion
modulates left ventricular structure in human essential hypertension.
Circulation 1996;94:1304–9.
20. Schunkert H, Hense HW, Holmer SR, et al. Association between a
deletion polymorphism of the angiotensin-converting enzyme gene
and left ventricular hypertrophy. N Engl J Med 1994;330:1634–8.
21. Lindpaintner K, Lee M, Larson MG, et al. Absence of association or
genetic linkage between the angiotensin-converting enzyme gene and
left ventricular mass. N Engl J Med 1996;334:1023–8.
22. Bonnardeaux A, Davies E, Jeunemaitre X, et al. Angiotensin II type 1
receptor gene polymorphisms in human essential hypertension. Hy-
pertension 1994;24:63–9.
23. Busjahn A, Knoblauch H, Knoblauch M, et al. Angiotensin-
converting enzyme and angiotensinogen gene polymorphisms, plasma
levels, cardiac dimensions: a twin study. Hypertension 1997;29:165–
70.
24. Benetos A, Gautier S, Ricard S, et al. Influence of angiotensin-
converting enzyme and angiotensin II type 1 receptor gene polymor-
phisms on aortic stiffness in normotensive and hypertensive patients.
Circulation 1996;94:698–703.
25. Amant C, Hamon M, Bauters C, et al. The angiotensin II type 1
receptor gene polymorphism is associated with coronary artery vaso-
constriction. J Am Coll Cardiol 1997;29:486–90.
26. Erdmann J, Folgmann I, Kallisch H, Fleck E, Regitz-Zagrosek V.
Three main haplotypes occurring in the promoter region of the human
angiotensin II subtype 1 receptor gene (abstr). Eur Heart J 1997;18:
445.
27. Takayanagi R, Ohnaka K, Sakai Y, Ikuyama S, Nawata H. Molecular
cloning and characterization of the promoter for human type-
1angiotensin II receptor gene. Biochem Biophys Res Commun 1994;
200:1264–70.
28. Janiak P, Pillon A, Prost JF, Vilaine JP. Role of angiotensin subtype 2
receptor in neointima formation after vascular injury. Hypertension
1992;20:737–45.
29. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation
of gene transcription of angiotensin II receptor subtypes in myocardial
infarction. J Clin Invest 1995;95:46–54.
30. Wharton J, Morgan K, Rutherford RA, et al. Differential distribution
of angiotensin AT2 receptors in the normal and failing human heart.
J Pharmacol Exp Ther 1998;284:323–36.
31. Regitz-Zagrosek V, Friedel N, Heymann A, et al. Regulation, cham-
ber localization and subtype distribution of angiotensin II receptors in
human hearts. Circulation 1995; 91:1461–71.
32. Lopez JJ, Lorell BH, Ingelfinger JR, et al. Distribution and function of
cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied
rat hearts. Am J Physiol 1994;267:H844–52.
33. Martin MM, Elton TS. The sequence and genetic organization of the
human type 2 angiotensin II receptor. Biochem Biophys Res Commun
1995;209:554–62.
34. Warnecke C, Willich T, Holzmeister J, Bottari S, Fleck E, Regitz-
Zagrosek V. Efficient transcription of the human angiotensin II type 2
receptor gene requires intronic sequence elements. Biochem J 1999;
340:17–24.
35. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T.
The angiotensin AT2-receptor mediates inhibition of cell proliferation
in coronary endothelial cells. J Clin Invest 1995;9:61–7.
36. Nakajima M, Hutchinson HG, Fujinaga M, et al. The angiotensin II
type 2 (AT2) receptor antagonizes the growth effects of the AT1
receptor: gain-of-function study using gene transfer. Proc Natl Acad
Sci USA 1995;92:10663–7.
37. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic
cyclic GMP in SHRSP by a kinin-dependent mechanism. Hyperten-
sion 1998;31:349–55.
38. Jalowy A, Schulz R, Dorge H, Behrends M, Heusch G. Infarct size
reduction by AT1-receptor blockade through a signal cascade of
AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am
Coll Cardiol 1998;32:1787–96.
39. Tsutsumi Y, Matsubara H, Ohkubo N, et al. Angiotensin II type 2
receptor is upregulated in human heart with interstitial fibrosis, and
cardiac fibroblasts are the major cell type for its expression. Circ Res
1998;83:1035–46.
40. Bartunek J, Weinberg EO, Tajima M, Rohrbach S, Lorell BH.
Angiotensin II type 2 receptor blockade amplifies the early signals of
cardiac growth response to angiotensin II in hypertrophied hearts.
Circulation 1999;99:22–5.
41. Senbonmatsu T, Ichihara S, Weinberger HD, Ichiki T, Gaffney AF,
Inagami T. Angiotensin II type 2 receptor is essential for the
181JACC Vol. 37, No. 1, 2001 Schmieder et al.
January 2001:175–82 AT2-Receptor Gene Variant and LV Structure
development of cardiac hypertrophy by pressure overload (abstr).
Circulation 1999;100:I–625.
42. Guidelines Subcommittee. 1999 World Health Organization-
international society of hypertension guidelines for the management of
hypertension. J Hypertens 1999;17:151–83.
43. Gatzka CD, Schmieder RE. Improved classification of dippers by
individualized analysis of ambulatory blood pressure profiles. Am J
Hypertens 1995;8:666–71.
44. Sahn DF, de Maria A, Kisslo J, Weyman A. Recommendations
regarding quantitation in M-mode echocardiography. Results of a
survey of echocardiographic measurements. Circulation 1978;58:
1072–80.
45. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic
assessment of left ventricular hypertrophy: comparison to necropsy
findings. Am J Cardiol 1986;56:450–8.
46. Budowle B, Chakraborty R, Giusti AM, Eisenberg AJ, Allen RC.
Analysis of the VNTR locus D1S80 by the PCR followed by
high-resolution PAGE. Am J Hum Genet 1991;48:137–44.
47. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation
of an angiotensin-converting enzyme gene polymorphism and the risk
of ischemic heart disease. N Engl J Med 1995;332:706–11.
48. Erdmann J, Shimron-Abarbanell D, Rietschel M, et al. Systematic
screening for mutations in the human serotonin-2A (5-HT2A) recep-
tor gene: identification of two naturally occurring receptor variants and
association analysis in schizophrenia. Hum Genet 1996;97:614–9.
49. Young MJ, Bresnitz EA, Strom BL. Sample size nomograms for
interpreting negative clinical studies. Ann Intern Med 1983;99:248–
51.
50. Pickering T. Recommendations for the use of home (self) and
ambulatory blood pressure monitoring. American Society of Hyper-
tension Ad Hoc Panel. Am J Hypertens 1996;9:1–11.
51. Devereux RB, Pickering TG, Harshfield GA, et al. Left ventricular
hypertrophy in patients with hypertension: importance of blood
pressure response to regularly recurring stress. Circulation 1983;68:
470–6.
52. Schmieder RE, Messerli FH. Does obesity influence early target organ
damage in hypertensive patients? Circulation 1993;87:1482–8.
53. Hilgers KF, Langenfeld MRW, Schlaich M, Veelken R, Schmieder
RE. 1166 A/C polymorphism of the angiotensin II type 1 receptor
gene and the response to short-term infused Ang II. Circulation
1999;100:1394–9.
54. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on
reversal of left ventricular hypertrophy in essential hypertension. A
meta-analysis of all randomized double-blind studies until December
1996. Nephrol Dial Transplant 1998;13:564–9.
182 Schmieder et al. JACC Vol. 37, No. 1, 2001
AT2-Receptor Gene Variant and LV Structure January 2001:175–82
